Midi Health Review 2026: Menopause-Specialist Telehealth With Insurance Coverage

What Is Midi Health?

Midi Health is a women's telehealth platform focused exclusively on perimenopause and menopause care for women 40 and older. Where most general telehealth services treat menopause as an afterthought, Midi has built its clinical model around it — recruiting providers who specialize in hormonal transitions and training them in evidence-based HRT protocols. The platform connects patients with these specialists via video visit, reviews their symptoms and health history, and can prescribe hormone replacement therapy for those who are appropriate candidates.

What sets Midi apart most sharply from competitors is its insurance integration. The platform accepts major insurance plans, and approximately 80% of PPO insurance plans cover HRT care through Midi at in-network rates. For patients who qualify, the out-of-pocket cost per visit can be as low as $0, with most paying a standard specialist copay in the $0–$30+ range. This makes Midi one of the most accessible menopause telehealth options for women who have PPO coverage and have been frustrated by primary care providers who minimize or dismiss their symptoms.

How Midi Health Works

Midi's intake process begins with an online symptom questionnaire covering hot flashes, sleep disruption, mood changes, brain fog, sexual health, and other common perimenopause and menopause complaints. Once you complete intake, Midi matches you with a clinician who specializes in menopause and schedules a video consultation. During that visit, the provider reviews your history, discusses treatment options — which may include bioidentical or conventional HRT, non-hormonal therapies, or lifestyle interventions — and issues any applicable prescriptions.

• Complete online symptom and health-history questionnaire
• Video consultation with a menopause-trained clinician
• HRT or non-hormonal prescription issued if clinically appropriate
• Prescriptions sent to your preferred pharmacy or via mail order
• Follow-up visits for medication management and dose adjustments
• Insurance billed directly for most PPO plans; self-pay option available

Labs are not bundled into Midi's standard plans. If your provider wants baseline hormone levels or metabolic markers before starting HRT, you will need to arrange those through your own primary care provider or a third-party lab service. This is common across telehealth platforms but worth knowing before your first visit.

Pricing: Insurance, Self-Pay, and GLP-1 Costs

Midi's pricing structure has three distinct tracks depending on how you access care. For insured PPO patients, the platform bills your insurance directly, and approximately 80% of PPO plans cover HRT care at in-network specialist rates. Most in-network patients pay a copay of $0–$30+ per visit, making this the most cost-effective path for eligible women. If your plan is an HMO, you are uninsured, or Midi is out of network for your plan, self-pay rates apply: $250 for an initial visit and $150 for follow-up appointments.

The third pricing track is Midi's GLP-1 weight management program, which offers compounded semaglutide starting at approximately $128 per month. This program was designed for women who need metabolic support alongside hormonal care — a common combination during the midlife transition, when estrogen decline accelerates visceral fat accumulation and insulin resistance. The GLP-1 program is priced separately from HRT visits and does not require insurance.

Annual cost estimate for HRT care depends heavily on visit frequency. A self-pay patient with one initial visit and three follow-ups per year would pay approximately $700 annually. An in-network PPO patient paying a $20 copay for four visits per year would pay roughly $80 annually. GLP-1 patients at the starting price would pay approximately $1,536 per year.

Providers and Clinical Quality

Midi's core differentiator is not technology — it is clinical focus. The platform recruits and trains clinicians specifically in menopause medicine, a subspecialty that is underrepresented in general practice. Many women in perimenopause report years of dismissal from primary care providers who normalized symptoms or offered antidepressants as a first-line response to hormonal decline. Midi's providers are oriented toward evidence-based HRT as a legitimate, often preferred treatment when clinically appropriate.

The provider mix includes physicians and nurse practitioners. While individual provider experience varies — as it does at any telehealth platform — the institutional emphasis on menopause-specific training gives Midi patients a higher baseline probability of speaking with someone who understands the nuance of perimenopause, including the long irregular window before final menstrual period that many platforms and providers fail to address adequately.

GLP-1 Weight Management: A Menopause-Integrated Option

Midi's GLP-1 program occupies an unusual position in the market: it is one of the few GLP-1 offerings embedded within a menopause-specialist practice rather than a general weight-loss platform. That context matters. Weight gain during perimenopause and menopause is driven by specific hormonal mechanisms — declining estrogen shifts fat storage toward the abdomen, and rising FSH levels correlate with metabolic changes that resist calorie restriction alone. A provider who understands those mechanisms can counsel GLP-1 patients differently than a generalist.

Midi offers compounded semaglutide starting at approximately $128 per month. Compounded semaglutide is the same active molecule as FDA-approved Ozempic and Wegovy but is produced by a 503A or 503B compounding pharmacy rather than the branded manufacturer. Patients considering compounded GLP-1s should be aware that the FDA has proposed removing semaglutide from the 503B bulk compounding list, which could affect availability and pricing for compounded versions in the medium term.

• Compounded semaglutide from approximately $128/mo
• Prescribed and managed by menopause-trained clinicians who understand midlife metabolism
• Designed to complement HRT care rather than replace it
• No insurance billing for GLP-1 program; self-pay only
• Labs not bundled; patients arrange monitoring separately

Who Midi Health Is Best For

Midi Health is the strongest fit for PPO-insured women in perimenopause or menopause who have been underserved by their primary care providers and want access to a specialist who will take their symptoms seriously. The insurance integration is a genuine advantage — for the majority of PPO patients, a specialist-level menopause consultation costs little more than a primary care copay, and the clinical focus is far sharper.

• Women 40+ experiencing perimenopause or menopause symptoms
• PPO-insured patients who want to use existing coverage for HRT care
• Women who have felt dismissed by generalist providers and want menopause specialists
• Patients seeking HRT who are appropriate candidates and want evidence-based guidance
• Women managing midlife weight changes who want GLP-1 support alongside hormonal care
• HMO or uninsured patients willing to pay self-pay rates of $250 initial / $150 follow-up

Midi is a weaker fit for women who need labs bundled into their plan, who are in states where Midi does not yet operate, or who want branded GLP-1 medications — Midi's weight management program focuses on compounded semaglutide and does not offer tirzepatide or branded medications at the same price point.

Verdict

Midi Health earns a strong recommendation for PPO-insured women who want expert menopause care without leaving their insurance network. The combination of specialist clinical training and direct insurance billing is rare in the menopause telehealth space, and for the majority of PPO patients, the cost barrier is effectively removed. The GLP-1 program adds useful metabolic support for women navigating the weight and insulin resistance changes that accompany hormonal decline.

The limitations are real: no bundled labs, not available in every state, and the GLP-1 offering carries the same medium-term regulatory uncertainty around compounded semaglutide that affects every platform in this space. But for a PPO-insured woman in her 40s or 50s who has been struggling to find a provider who takes her symptoms seriously and accepts her insurance, Midi is one of the best options currently available.